uniQure NV logo

uniQure NVNASDAQ: QURE

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Netherlands

IPO:

05 February 2014

Next earnings report:

07 November 2024

Last dividends:

N/A

Next dividends:

N/A
$285.37 M
-82%vs. 3y high
58%vs. sector
-vs. 3y high
-vs. sector
-40%vs. 3y high
69%vs. sector
-58%vs. 3y high
76%vs. sector

Price

after hours | Fri, 01 Nov 2024 21:16:16 GMT
$5.86+$0.14(+2.45%)

Dividend

No data over the past 3 years
$11.13 M$6.79 M
$11.13 M-$56.30 M

Analysts recommendations

Institutional Ownership

QURE Latest News

UniQure (QURE) Reports Q2 Loss, Tops Revenue Estimates
zacks.com01 August 2024 Sentiment: POSITIVE

UniQure (QURE) came out with a quarterly loss of $1.16 per share versus the Zacks Consensus Estimate of a loss of $1.24. This compares to loss of $1.44 per share a year ago.

uniQure Announces Closing of Sale of Manufacturing Facility to Genezen
globenewswire.com23 July 2024 Sentiment: POSITIVE

~ uniQure maintains preferential access to industry-leading manufacturing capabilities to support its pipeline of gene therapy candidates ~

What Led To A 150% Rise In UniQure Stock In A Week?
forbes.com12 July 2024 Sentiment: POSITIVE

uniQure stock (NASDAQ: QURE), a gene therapy company, has seen a stellar 150% rise in a week, faring significantly better than its peer – Editas Medicine stock –, up 12%. This massive rise in QURE stock can be attributed to the positive outcome from its phase I-II clinical trials of AMT-130 for Huntington's disease.

Wall Street Analysts Think uniQure (QURE) Could Surge 195.8%: Read This Before Placing a Bet
zacks.com10 July 2024 Sentiment: POSITIVE

The consensus price target hints at a 195.8% upside potential for uniQure (QURE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

uniQure (QURE) Soars on New Huntington's Disease Study Data
zacks.com10 July 2024 Sentiment: POSITIVE

uniQure (QURE) surges 77% on updated positive interim data from 29 treated patients in the ongoing phase I/II studies of investigational gene therapy, AMT-130, for Huntington's disease.

uniQure (QURE) Surges 76.5%: Is This an Indication of Further Gains?
zacks.com10 July 2024 Sentiment: POSITIVE

uniQure (QURE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA
prnewswire.com01 July 2024 Sentiment: POSITIVE

Strategic acquisition will enable Genezen to deliver late-phase and commercial gene therapy development and manufacturing services to customers around the world. BOSTON and INDIANAPOLIS , July 1, 2024 /PRNewswire/ -- Genezen, a best-in-class gene therapy CDMO, today announced an agreement to acquire uniQure's (Nasdaq: QURE) commercial gene therapy operations in Lexington, MA, bringing a strategic manufacturing facility and a world-class team of employees to the company.

UniQure (QURE) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research28 February 2024 Sentiment: POSITIVE

UniQure (QURE) came out with a quarterly loss of $1.53 per share versus the Zacks Consensus Estimate of a loss of $1.54. This compares to earnings of $0.15 per share a year ago.

UniQure (QURE) Reports Q3 Loss, Lags Revenue Estimates
Zacks Investment Research07 November 2023 Sentiment: NEGATIVE

UniQure (QURE) came out with a quarterly loss of $1.88 per share versus the Zacks Consensus Estimate of a loss of $1.49. This compares to loss of $1.02 per share a year ago.

uniQure (QURE) Up on Restructuring Plans, Workforce Reduction
Zacks Investment Research06 October 2023 Sentiment: POSITIVE

uniQure (QURE) gains on plans to discontinue investment in some projects and reduce 20% of its workforce.

  • 1(current)

What type of business is uniQure NV?

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

What sector is uniQure NV in?

uniQure NV is in the Healthcare sector

What industry is uniQure NV in?

uniQure NV is in the Biotechnology industry

What country is uniQure NV from?

uniQure NV is headquartered in Netherlands

When did uniQure NV go public?

uniQure NV initial public offering (IPO) was on 05 February 2014

What is uniQure NV website?

https://www.uniqure.com

Is uniQure NV in the S&P 500?

No, uniQure NV is not included in the S&P 500 index

Is uniQure NV in the NASDAQ 100?

No, uniQure NV is not included in the NASDAQ 100 index

Is uniQure NV in the Dow Jones?

No, uniQure NV is not included in the Dow Jones index

When was uniQure NV the previous earnings report?

No data

When does uniQure NV earnings report?

The next expected earnings date for uniQure NV is 07 November 2024